Nureca Limited Approves ₹100 Cr Capex; Key Leadership Appointments

Nureca Limited's Board, in its meeting on May 29, 2026, approved several strategic decisions to strengthen operational capacity and governance: 1. Capital Expenditure: Approved incremental capex of up to ₹100 crore in plant and machinery to enhance production capabilities and support future growth initiatives. 2. Leadership Changes: Chander Kant Chief Financial Officer Appointed (ex-Manager Finance) June 27, 2026 Naresh Gupta CFO Resigned (better opportunities) June 26, 2026 Saurabh Goyal Managing Director Reappointed (3 years) Sept 3, 2026* Aryan Goyal Whole-time Director Reappointed (3 years) May 28, 2027* Smita Goyal Additional Director (WTD) Appointed (3 years) June 1, 2026* *Subject to shareholder approval at ensuing AGM 3. Governance: Reappointed M/s. MGSG and Associates as internal auditor for FY27 to ensure continued financial oversight and compliance. Strategic Context: The ₹100 Cr capex signals confidence in demand visibility for Nureca's healthcare brands (e.g., Equilibre, Dr. Morepen) and intent to scale manufacturing efficiency. Leadership continuity via reappointments of promoter directors, coupled with internal promotion of Chander Kant as CFO, ensures strategic alignment and operational stability during a growth phase. Outlook: With enhanced capacity and a reinforced leadership team, Nureca is positioned to execute its premiumization and category expansion strategy. Investor focus will shift to capex deployment timelines and margin trajectory post-investment. $NURECA